Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Phthisis Diagnostics Launches New Product Line

Published: Monday, October 01, 2012
Last Updated: Monday, October 01, 2012
Bookmark and Share
G-Sphere® Molecular Standards provides flexible quality control for labs.

Phthisis Diagnostics has just rolled out its new molecular standards product line, the G-Sphere® Molecular Standards.

The new line quickly follows the introduction of the company’s second product in its Simply Molecular® line of enzyme-based extraction kits for rapid sample preparation prior to PCR applications in laboratories.

Phthisis Diagnostics, based in Charlottesville, VA, is a rapidly growing biotechnology company developing a range of innovative molecular diagnostics technologies.

The G-Sphere® Molecular Standards are synthetic genes that provide safe, stable, consistent, and abundant controls for virtually any organism and any molecular assay.

Molecular diagnostic laboratories face difficulties in obtaining consistent and reliable controls to monitor the performance of molecular assays and instruments.

This new Phthisis product line, the only one currently offering such standards for parasites, is an innovative solution to improve and simplify quality control procedures.

The Company has expanded its staff to allow special focus on the development of the new line. Elizabeth Nelson is a Research Technician designated as the Project Lead for the G-Sphere® Molecular Standards.

This custom product is supplied as 100 reaction vials that come with dilution buffer and instructions for use. In addition to custom orders, a growing list of G-Sphere® Molecular Standards have been developed for various parasites, including Cryptosporidium, Giardia, Entamoeba, Plasmodium, Microsporidia, and other analytes of particular interest to public health laboratories.

“This new product provides much needed quality control standards to molecular laboratories,” explains Crystal Icenhour, PhD, President and Chief Science Officer at Phthisis Diagnostics.

Icenhour continued, “We have developed a consensus approach to creating molecular standards, giving the users greater flexibility. We are excited to introduce this product line because it will enable molecular laboratories to better control diagnostic assays. In addition to being a stand-alone product, these molecular standards will be used as positive controls for our diagnostic product line.”

Phthisis Diagnostics will be presenting its new product line for the first time at the 2012 Association for Molecular Pathology (AMP) Annual Meeting in Long Beach, CA, in October.

Interested laboratories are encouraged to stop by Phthisis’ Booth # 332 at this meeting to learn more about G-Sphere® Molecular Standards.

Phthisis Diagnostics products are developed and manufactured in the USA to ISO 13485 standards in a QSR and cGMP compliant facility and are designated as general purpose reagents.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Phthisis Diagnostics Announces Second Round of Funding
With their first product already in the international marketplace and a second just launched, Phthisis Diagnostics has announced a successful second round of angel funding.
Thursday, July 12, 2012
Phthisis Diagnostics Announces First International Distribution Agreement
Simple and cost-efficient molecular products make their way into Latin America.
Friday, May 25, 2012
Phthisis Diagnostics Welcomes New Sales Director and Controller
Appointment of Betty Polk and Robert Owen to Company’s management team.
Monday, May 14, 2012
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!